A Sequential Dose-Escalation, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Single Doses of 3 Different Doses of Oral CNDO 201 Trichuris Suis Ova Suspension (Tso) in Patients With Crohn's Disease.

Trial Profile

A Sequential Dose-Escalation, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Single Doses of 3 Different Doses of Oral CNDO 201 Trichuris Suis Ova Suspension (Tso) in Patients With Crohn's Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2013

At a glance

  • Drugs Trichuris suis ova (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 01 May 2012 Results from this trial presented at the 8th International Congress on Autoimmunity in May 2012, according to a Coronado Biosciences media release
    • 13 Apr 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Status changed from active, no longer recruiting to completed, according to results published in a Coronado Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top